Abstract
The antiviral efficacy of acyclic nucleoside phosphonates, including 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine [(R)-PMPDAP] against feline immunodeficiency virus (FIV) infection was determined. (R)-PMPDAP showed the highest selectivity index (> 2,000) in vitro. Treatment of experimentally FIV-infected asymptomatic cats with PMEA or (R)-PMPDAP had no effect on the CD4+/CD8+ ratio. However, mean plasma viral RNA concentrations decreased significantly in the (R)-PMPDAP-treated cats. Our data show that, in comparison to PMEA, (R)-PMPDAP is a more potent and less toxic inhibitor of FIV replication both in vitro and in vivo.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / pharmacokinetics
-
Adenine / therapeutic use
-
Animals
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / therapeutic use*
-
Cats
-
Feline Acquired Immunodeficiency Syndrome / drug therapy*
-
Feline Acquired Immunodeficiency Syndrome / metabolism
-
Immunodeficiency Virus, Feline*
-
In Vitro Techniques
-
Organophosphorus Compounds / pharmacokinetics
-
Organophosphorus Compounds / therapeutic use*
-
RNA, Viral / biosynthesis
-
T-Lymphocytes / virology
-
Virus Replication / drug effects
Substances
-
9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine
-
Antiviral Agents
-
Organophosphorus Compounds
-
RNA, Viral
-
Adenine